Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Bioventus (NASDAQ:BVS) is the #1 top healthcare stock out of 1062 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Bioventus (NASDAQ:BVS) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Bioventus (NASDAQ:BVS) has a Due Diligence Score of 44, which is 18 points higher than the healthcare sector average of 26. It passed 14 out of 33 due diligence checks and has strong fundamentals. Bioventus has seen its stock return 90.66% over the past year, overperforming other healthcare stocks by 186 percentage points.

Bioventus has an average 1 year price target of $15.00, an upside of 20.48% from Bioventus's current stock price of $12.45.

Bioventus stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Bioventus, 33.33% have issued a Strong Buy rating, 66.67% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Jazz Pharmaceuticals (NASDAQ:JAZZ) is the #2 top healthcare stock out of 1062 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Jazz Pharmaceuticals (NASDAQ:JAZZ) is: Value: A, Growth: A, Momentum: B, Sentiment: C, Safety: C, Financials: B, and AI: C.

Jazz Pharmaceuticals (NASDAQ:JAZZ) has a Due Diligence Score of 34, which is 8 points higher than the healthcare sector average of 26. It passed 11 out of 33 due diligence checks and has average fundamentals. Jazz Pharmaceuticals has seen its stock return 117.62% over the past year, overperforming other healthcare stocks by 213 percentage points.

Jazz Pharmaceuticals has an average 1 year price target of $269.21, an upside of 5.4% from Jazz Pharmaceuticals's current stock price of $255.43.

Jazz Pharmaceuticals stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 14 analysts covering Jazz Pharmaceuticals, 71.43% have issued a Strong Buy rating, 21.43% have issued a Buy, 7.14% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Electromed (NYSEMKT:ELMD) is the #3 top healthcare stock out of 1062 with a Zen Rating of A. Stocks with a rating of A have had an average return of +28.5% per year. Learn more.

The Component Grade breakdown for Electromed (NYSEMKT:ELMD) is: Value: C, Growth: C, Momentum: B, Sentiment: A, Safety: B, Financials: A, and AI: C.

Electromed (NYSEMKT:ELMD) has a Due Diligence Score of 49, which is 23 points higher than the healthcare sector average of 26. It passed 17 out of 33 due diligence checks and has strong fundamentals. Electromed has seen its stock return 111.68% over the past year, overperforming other healthcare stocks by 207 percentage points.

Electromed has an average 1 year price target of $38.00, a downside of -4.67% from Electromed's current stock price of $39.86.

Electromed stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Electromed, 100% have issued a Strong Buy rating, 0% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 79 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Vyne Therapeutics (NASDAQ:VYNE) has an annual dividend yield of 70.37%, which is 67 percentage points higher than the healthcare sector average of 3.85%.

Vyne Therapeutics's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 39.31%, which is 35 percentage points higher than the healthcare sector average of 3.85%.

Dominari Holdings's dividend payout ratio of -19.1% indicates that its high dividend yield might not be sustainable for the long-term.

Cumberland Pharmaceuticals (NASDAQ:CPIX) has an annual dividend yield of 21.34%, which is 17 percentage points higher than the healthcare sector average of 3.85%.

Cumberland Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were up 0.58% in the last day, and up 1.28% over the last week. Entera Bio was the among the top gainers in the healthcare sector, gaining 91.22% yesterday.

Entera Bio shares are trading higher after the company announced pricing of oversubscribed $275 million private placement.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Embecta (NASDAQ:EMBC) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Embecta has a valuation score of 43, which is 29 points higher than the healthcare sector average of 14. It passed 3 out of 7 valuation due diligence checks.

Embecta's stock has dropped -69.68% in the past year. It has overperformed other stocks in the healthcare sector by 26 percentage points.

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Ironwood Pharmaceuticals has a valuation score of 57, which is 43 points higher than the healthcare sector average of 14. It passed 4 out of 7 valuation due diligence checks.

Ironwood Pharmaceuticals's stock has gained 389.36% in the past year. It has overperformed other stocks in the healthcare sector by 485 percentage points.

Collegium Pharmaceutical (NASDAQ:COLL) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Collegium Pharmaceutical has a valuation score of 43, which is 29 points higher than the healthcare sector average of 14. It passed 3 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 13.27% in the past year. It has overperformed other stocks in the healthcare sector by 109 percentage points.

63.14% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 32.07% over the next year.

5.1% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.31% of healthcare stocks are rated B (Buy), 46.27% are rated C (Hold), 29.23% are rated D (Sell), and 7.09% are rated F (Strong Sell).